In the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48 (ENGAGE-AF TIMI 48) trial, patients were randomly assigned to either the high-dose (60 mg) or low-dose group (30 mg) without any adjustment criteria, followed by dose halving for those with estimated creatinine clearance of 30–50 mL/min, body weight ≤ 60 kg [23]. This evidence concerns the gene F10 and atrial fibrillation.